2022 in Review: Allergen Immunotherapy

7.7K

views

34

authors

5

articles

2022 in Review: Allergen Immunotherapy

7.7K

views

34

authors

5

articles

Editors

2

Michael D Kulis

University of North Carolina at Chapel Hill

Impact

About

2022 in Review: Allergen Immunotherapy will publish high-quality scholarly review papers on key topics relating to allergen immunotherapy. It aims to highlight recent advances in the field, whilst emphasizing important directions and new possibilities for future inquiries. We anticipate the research presented will promote discussion in the scientific community that will translate to best practice applications in clinical, public health and policy settings.

The collection 2022 in Reviews: Allergen Immunotherapy welcomes full-length, mini or systematic review papers around any aspect of allergen immunotherapy. Themes around our most impactful research articles of 2022 will be welcomed; these include, but are not limited to:

Dropouts From Sublingual Immunotherapy and the Transition to Subcutaneous Immunotherapy in House Dust Mite-Sensitized Allergic Rhinitis Patients

Intralymphatic Immunotherapy (ILIT) With Bee Venom Allergens: A Clinical Proof-of-Concept Study and the Very First ILIT in Humans

The MaDo real-life study of dose adjustment of allergen immunotherapy liquid formulations in an indication of respiratory allergic disease: Reasons, practices, and outcomes

Manufacturing processes of peanut (Arachis hypogaea) allergen powder-dnfp

New articles will be added to this collection as they are published.

Conflict of Interest Declaration: Michael Kulis receives funding from NIH and DoD, and consults for UKKO.

2022 in Review: Allergen Immunotherapy will publish high-quality scholarly review papers on key topics relating to allergen immunotherapy. It aims to highlight recent advances in the field, whilst emphasizing important directions and new possibilities for future inquiries. We anticipate the research presented will promote discussion in the scientific community that will translate to best practice applications in clinical, public health and policy settings.

The collection 2022 in Reviews: Allergen Immunotherapy welcomes full-length, mini or systematic review papers around any aspect of allergen immunotherapy. Themes around our most impactful research articles of 2022 will be welcomed; these include, but are not limited to:

Dropouts From Sublingual Immunotherapy and the Transition to Subcutaneous Immunotherapy in House Dust Mite-Sensitized Allergic Rhinitis Patients

Intralymphatic Immunotherapy (ILIT) With Bee Venom Allergens: A Clinical Proof-of-Concept Study and the Very First ILIT in Humans

The MaDo real-life study of dose adjustment of allergen immunotherapy liquid formulations in an indication of respiratory allergic disease: Reasons, practices, and outcomes

Manufacturing processes of peanut (Arachis hypogaea) allergen powder-dnfp

New articles will be added to this collection as they are published.

Conflict of Interest Declaration: Michael Kulis receives funding from NIH and DoD, and consults for UKKO.

Share

Editors

Michael D Kulis

University of North Carolina at Chapel Hill

Impact

7,718 Total views

5,831 Article views

1,531 Article downloads

356 Topic views

Published In

Journal Thumbnail

Frontiers in Allergy

Food Allergy, Allergen Immunotherapy

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic